Police & Firemen s Retirement System of New Jersey Sells 6,777 Shares of Azenta, Inc. $AZTA

Police & Firemen s Retirement System of New Jersey trimmed its position in shares of Azenta, Inc. (NASDAQ:AZTA) by 43.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,756 shares of the company’s stock after selling 6,777 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Azenta were worth $270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in AZTA. Allspring Global Investments Holdings LLC lifted its position in shares of Azenta by 35.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,345,250 shares of the company’s stock valued at $42,725,000 after purchasing an additional 350,930 shares in the last quarter. Nuveen LLC purchased a new stake in Azenta in the 1st quarter valued at about $11,604,000. Geode Capital Management LLC lifted its position in shares of Azenta by 38.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,064,464 shares of the company’s stock worth $32,769,000 after buying an additional 297,353 shares in the last quarter. Millennium Management LLC lifted its position in shares of Azenta by 214.8% during the 1st quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock worth $11,798,000 after buying an additional 232,405 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in shares of Azenta by 27.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 747,801 shares of the company’s stock worth $25,904,000 after buying an additional 161,454 shares during the last quarter. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Needham & Company LLC increased their price target on Azenta from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, November 21st. Zacks Research lowered Azenta from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Evercore ISI set a $33.00 price target on shares of Azenta and gave the stock an “in-line” rating in a report on Tuesday, August 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Azenta in a research report on Monday. Finally, Jefferies Financial Group raised shares of Azenta from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $30.00 to $38.00 in a research report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Azenta currently has an average rating of “Hold” and an average price target of $38.60.

Azenta Price Performance

Shares of NASDAQ AZTA opened at $36.27 on Friday. The stock has a market capitalization of $1.66 billion, a PE ratio of -14.99 and a beta of 1.65. Azenta, Inc. has a one year low of $23.91 and a one year high of $55.63. The business’s fifty day moving average price is $31.20 and its 200-day moving average price is $30.57.

Azenta (NASDAQ:AZTA) last announced its quarterly earnings data on Friday, November 21st. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. The company had revenue of $159.19 million during the quarter, compared to analyst estimates of $156.76 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.18 EPS. As a group, equities analysts expect that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.